Search for a trial

1 results

A Phase 4, Open-label, Multicentre, 2-Year Safety Study of
Lisdexamfetamine Dimesylate in Children and Adolescents Aged
6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

Approved WMORecruitment stopped

Primary: The primary objective of this study is to evaluate the long-term safety of SPD489 administered as adaily morning dose (30, 50, and 70mg) in the treatment of children and adolescents (6-17 years of ageinclusive at the time of consent in this…

A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 4, Open-label, Multicentre, 2-Year Safety Study of
Lisdexamfetamine Dimesylate in Children and Adolescents Aged
6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)